Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety.

Int Clin Psychopharmacol

Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore 21228, USA.

Published: February 1997

Evidence from clinical trials supports the claim that sertindole is a potent antipsychotic drug at a dose of 12-24 mg/day. Its action against positive symptoms is as potent as that of the traditional antipsychotic haloperidol. Its action against negative symptoms is significantly different from that of placebo and quantitatively larger than that of haloperidol. Its most distinctive characteristic is a reduction in motor side effects over a whole range of comparable drug and comparator doses. More work is needed to determine whether sertindole's actions against negative symptoms influence the primary or the secondary negative system. There are insufficient data at present to compare sertindole with the highly efficacious drug clozapine or the other new antipsychotic olanzapine.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00004850-199702001-00005DOI Listing

Publication Analysis

Top Keywords

negative symptoms
8
sertindole treatment
4
treatment psychosis
4
psychosis schizophrenia
4
schizophrenia efficacy
4
efficacy safety
4
safety evidence
4
evidence clinical
4
clinical trials
4
trials supports
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!